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OBJECTIVE — Insulinoma-associated protein 2 (IA-2) is a major autoantigen in type 1 dia-
betes, and IA-2 autoantibodies are routinely detected by a liquid-phase radioimmunoprecipita-
tion assay. The present experiments were initiated to develop a new assay that does not require
the use of radioisotopes or autoantigens prepared in bacteria or by in vitro transcription/
translation.
RESEARCH DESIGN AND METHODS — IA-2 luciferase fusion protein was ex-
pressed in mammalian cells and assayed for autoantibodies by liquid-phase luciferase
immunoprecipitation.
RESULTS — Ourstudyshowedthattherewasnosigniﬁcantdifferencebetweentheluciferase
immunoprecipitation and the radioimmunoprecipitation assays in sensitivity and speciﬁcity,
and comparison of the two assays revealed a high correlation coefﬁcient (R
2  0.805).
CONCLUSIONS — The luciferase system offers a robust, inexpensive, nonradioactive
method for the detection of autoantibodies to mammalian cell–prepared IA-2 and could be of
practical value at the clinical level.
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I
nsulinoma-associated protein 2 (IA-2)
is a major autoantigen in type 1 diabe-
tes (1). IA-2 autoantibodies appear
years before the development of clinical
disease and, in combination with autoan-
tibodies to GAD and insulin, are used as
predictive markers (2). The liquid-phase
radioimmunoprecipitation (RIP) assay is
a highly sensitive and reproducible assay
for IA-2 autoantibodies. Luminescence,
using recombinantly expressed proteins
fused to luciferase (3–5), is an alternative
to the radioactive assay. In the present ar-
ticle, we describe a liquid-phase lumines-
cence immunoprecipitation system
(LIPS) assay for IA-2 autoantibodies, in
which we used IA-2 luciferase fusion pro-
tein expressed in mammalian cells rather
than IA-2–radiolabeled protein produced
by in vitro transcription/translation. Our
study showed that LIPS offers a highly
sensitive, robust, nonradioactive method
forthedetectionofIA-2autoantibodiesin
type 1 diabetes.
RESEARCH DESIGN AND
METHODS—In the LIPS assay, IA-2
(amino acids 601–979) was cloned into
thepREN2mammalianexpressionvector
downstream of the Renilla luciferase
(Ruc) reporter (3–5). Monkey kidney
cells (Cos1) in a 100 mm
2 dish were
transfected, and 48 h later, the cells were
sonicated, clariﬁed by centrifugation, and
the extract (enough for 1,500 assays in
duplicate) used without further puriﬁca-
tion.Totalluciferaseactivityintheextract
was measured in a luminometer and ad-
justed so that each reaction contained
1.010
7light-formingunitsper0.1l
ofextract.Theextractwasthenincubated
with 1.0 l of sera for1ha troom tem-
perature in a total volume of 100 l,
transferred to 96-well ﬁltration plates
containing7lof30%suspensionofpro-
tein A/G beads (Pierce Biochem), and in-
cubated for an additional hour. The A/G
beads with the captured antibody–
luciferase labeled IA-2 complexes were
washed using a BioMek-FX workstation,
Renilla luciferase substrate (Promega,
Madison, WI) was added, and the light-
forming units were determined in a Mi-
croplate Luminometer (Berthold
Technologies, Bad Wildbad, Germany).
In the RIP assay, performed as previ-
ouslydescribed(6),thesameintracellular
portionofIA-2usedintheLIPSassaywas
cloned into a pGBKT7 vector (Clontech,
Mountain View, CA), and the IA-2 pro-
tein was produced by in vitro transcrip-
tion/translation in the presence of
35S-
methionine. IA-2 autoantibodies were
detected by liquid-phase radioimmuno-
precipitation using 20,000 cpm of ra-
diolabeled IA-2.
A total of 100 sera from patients with
newly diagnosed type 1 diabetes who had
beenpreviouslyscreenedforIA-2autoan-
tibodies by RIP were selected on the basis
of the counts precipitated, from very high
tomoderateandlowtonegative.Atotalof
100 sera from age-matched nondiabetic
individuals served as the control (6). A
serumwasscoredaspositiveiftheprecip-
itated cpm exceeded the mean  3S Do f
the control subjects.
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1824 DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008Figure 1—IA-2 autoantibodies as determined by RIP (A) and LIPS (B). C: Correlation between RIP and LIPS evaluated by the coefﬁcient of
determination (R
2  0.805). D: Comparison by RIP and LIPS of 25 sera at the borderline of positivity for IA-2 autoantibodies. Closed triangles
represent the 5 sera that were determined to be positive by RIP but negative by LIPS. Dotted lines represent 3 SD above the mean of control subject
sera. E: Receiver operating characteristic analysis showed that the area under the curve for IA-2 by RIP was 0.985 (95% CI 0.956–0.997) and by
LIPS was 0.963 (95% CI 0.925–0.985). There was no statistical difference (P  0.120).
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100) and control subjects (n  100) were
screened for IA-2 autoantibodies by RIP
assay. Only one of the control subject sera
fell outside the 3 SD range, whereas 90% of
the diabetic subject sera exceeded the 3 SD
range of the control subject sera (Fig. 1A).
The coefﬁcient of variation (CV) for dupli-
catesamplesofthediabeticsubjectserawas
5.0%.
The same sera were screened for IA-2
autoantibodiesbyLIPSassay.Noneofthe
control subject sera fell outside the 3 SD
range, whereas 85% of the diabetic sub-
ject sera exceeded the 3 SD range of the
control subject sera (Fig. 1B). The CV of
the diabetic subject sera was 9.3%.
Comparison of the RIP and LIPS as-
says revealed a high correlation, with a
0.805 coefﬁcient of determination (R
2)
(Fig. 1C). Evaluation of the 5 diabetic
subjectserathatwerenegativebytheLIPS
assay but positive by the RIP assay
showed that 3 of the 5 negative sera were
at the very borderline of positivity (Fig.
1D).
Receiver operating characteristic anal-
ysis showed that the areas under the curves
for IA-2 by RIP and LIPS were not statisti-
cally different (P  0.120) (Fig. 1E).
CONCLUSIONS —From these ex-
periments, we concluded that there was
no signiﬁcant difference in sensitivity or
speciﬁcity between the LIPS and RIP as-
says. However, the LIPS assay offers sev-
eral potential advantages. First, because it
uses luminescence rather than radioactiv-
ity, it lends itself better to most clinical
laboratories and can be easily automated.
Second, because the preparation of the
protein does not require in vitro tran-
scription/translation, the protein can be
preparedatafractionofthecostoftheRIP
assay. Third, because the recombinant
protein is fused with a luminescence
marker, it does not need to be externally
labeled or laboriously separated from the
other proteins in the mammalian cell ly-
sate, thereby eliminating the puriﬁcation
steps required for both bacteria-prepared
proteins (7) used in solid-phase enzyme-
linked immunosorbent assays. Fourth,
becausetheproteinsaremadeinmamma-
lian cells, they may undergo a variety of
processing and posttranslational modiﬁ-
cations that do not occur when they are
prepared via in vitro transcription/
translationand,therefore,maymoretruly
reﬂectthenaturalstateoftheautoantigen.
It will be of interest to see if this increases
detection and/or sensitivity when other
autoantigens, prepared in mammalian
cells, are screened for autoantibodies.
Our ﬁndings suggest that the LIPS as-
saymaybeofpracticalvalueattheclinical
level for the detection of autoantibodies
not only for diabetes, but also for other
autoimmune diseases. However, as with
all new assays, LIPS requires validation
with a large number of sera and compar-
ison with RIP in a Diabetes Autoantibody
Standardization Program workshop.
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